{"organizations": [], "uuid": "3be37b8dc6a024ce52624ca0922509cb6bbd86e1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180521.html", "section_title": "Archive News &amp; Video for Monday, 21 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-approves-prolia-for-glucocorti/brief-fda-approves-prolia-for-glucocorticoid-induced-osteoporosis-idUSASC0A33K", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Approves Prolia For Glucocorticoid-Induced Osteoporosis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.916, "site_type": "news", "published": "2018-05-22T04:03:00.000+03:00", "replies_count": 0, "uuid": "3be37b8dc6a024ce52624ca0922509cb6bbd86e1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-approves-prolia-for-glucocorti/brief-fda-approves-prolia-for-glucocorticoid-induced-osteoporosis-idUSASC0A33K", "ord_in_thread": 0, "title": "BRIEF-FDA Approves Prolia For Glucocorticoid-Induced Osteoporosis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "amgen inc", "sentiment": "negative"}, {"name": "osis", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) - Amgen Inc:\n* FDA APPROVES PROLIA® (DENOSUMAB) FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS\n* FDA APPROVES PROLIA® (DENOSUMAB) FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS\n* AMGEN INC - SAFETY RESULTS WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF PROLIA\n* AMGEN INC - APPROVAL OF PROLIA FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS IS BASED ON DATA FROM A PHASE 3 STUDY Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-22T04:03:00.000+03:00", "crawled": "2018-05-22T19:18:34.056+03:00", "highlightTitle": ""}